NCT04963153 2026-03-18
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
6 trialsNCT05567185 2026-03-13
TAR-210
Janssen Pharmaceutical K.K.
Phase 1 Active not recruiting
NCT04172675 2026-02-24
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Phase 2 Completed
NCT05564416 2025-10-21
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT04917809 2025-09-10
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05052372 2022-12-22
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
xCures
Terminated